Abstract 1071P
Background
The utilization of immune checkpoint inhibitors (ICIs) has become increasingly prevalent in cancer treatment. However, ICIs may also precipitate a spectrum of immune-related adverse events, which can target various organ systems. Among these, pulmonary immune-related adverse events (pirAEs) are the leading cause of ICI cessation and mortality.
Methods
Individual Case Safety Reports (ICSRs) were obtained from FAERS and VigiBase. We identified reports pertaining to eight ICIs for the purposes of this study, namely nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, and tremelimumab. Subsequently, we utilized expert consensus to select 52 significant pirAEs with high incidence or of clinical significance and then evaluated the incidence and mortality of pirAEs across varying time periods following the initiation of ICIs therapy.
Results
16,372 and 7,943 ICSRs were collected using FAERS and VigiBase, respectively. More than 50% of pirAEs occurred within 60 days after treatment with ICIs (FAERS:70.0%,VigiBase:55.7%), and their mortality was higher than that after 60 days (15% vs 12%, 12% vs 7%). In each period after the use of ICIs, pirAEs with the highest incidence were interstitial lung disease (14.6%,26.4%), dyspnoea (18.4%,17.0%)and pneumonitis (13.0%,17.0%). The all-cause mortality of respiratory failure (30%, 58%), pulmonary hemorrhage (28%,57%), acute interstitial pneumonitis (75%, 27%), and stridor (31%, 30%)was over 25%. The mortality of respiratory failure remained stable at a high level in each period after initiation of immune therapy (24-40%, 42-69%).
Conclusions
Using data from the FAERS and VigiBase, we conducted an analysis of the frequency and incidence of pirAEs during varied periods after the onset of ICIs therapy. We offer a groundbreaking revelation, identifying the occurrence of pirAEs which manifest early on, within the initial 60 days of treatment, and exhibit a high incidence and mortality rate. Among pirAEs, interstitial lung disease, dyspnea, and pneumonitis were most frequently reported with respiratory failure being a consistently fatal adverse event highlighting the necessity of heightened physician vigilance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19